Adaptimmune Therapeutics plc - American Depositary Shares (ADAP)
0.3050
+0.0550 (22.00%)
NASDAQ · Last Trade: Apr 3rd, 2:17 AM EDT
Detailed Quote
Previous Close
0.2500
Open
0.2530
Bid
0.2810
Ask
0.2975
Day's Range
0.2449 - 0.3224
52 Week Range
0.1951 - 1.480
Volume
6,755,920
Market Cap
468.37M
PE Ratio (TTM)
-6.100
EPS (TTM)
-0.1
Dividend & Yield
N/A (N/A)
1 Month Average Volume
2,782,284
About Adaptimmune Therapeutics plc - American Depositary Shares (ADAP)
Adaptimmune is a biotechnology company focused on developing T-cell therapy to treat cancer. The company specializes in harnessing the power of the immune system, particularly using engineered T-cell receptors (TCRs), to target and eliminate cancer cells more effectively. Adaptimmune’s innovative approach aims to improve patient outcomes in various cancers by personalizing therapies to the individual’s unique tumor characteristics. Through ongoing research and clinical trials, the company strives to bring transformative treatment options to patients suffering from life-threatening malignancies. Read More
Intrigued by the market activity in the middle of the day on Thursday? Uncover the key winners and losers of today's session in our insightful analysis.
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - March 12, 2025) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining...
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - January 30, 2025) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company working...
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - November 5, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company working...
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - October 31, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining...
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - August 28, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company working to...
